文献速递慢性肾脏病遗传性与小管间质肾病

较高β-羟丁酸酮体水平与ADPKD肾功能下降较慢相关

Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

在DIPAK多中心前瞻性观察队列521例ADPKD患者中,基线BHB中位数94 µmol/L;纵向分析显示BHB与eGFR斜率正相关(B=0.35 mL/min/1.73 m²,95%CI 0.09–0.61,P=.007),BHB每翻倍与eGFR年变化率改善0.33 mL/min/1.73 m²相关(95%CI 0.09–0.57,P=.008),但与肾脏增长无关。

要点

  • ADPKD患者中较高内源性BHB与eGFR下降较慢相关,与肾脏增长无关。
  • BHB每翻倍与eGFR年变化率改善0.33 mL/min/1.73 m²相关(95%CI 0.09–0.57)。
  • 横断面分析中BHB与eGFR及htTKV均无关联。

核心结论

  • 这些观察性分析支持以下假设:提高BHB浓度的干预可能降低ADPKD患者肾功能下降速率。

研究设计与样本

  • 研究分析DIPAK多中心前瞻性观察队列中670例ADPKD患者数据,排除2型糖尿病、使用疾病修饰药物、非空腹或BHB缺失者后,521例纳入分析。
  • 基线BHB采用核磁共振波谱法测定;横断面关联用线性回归分析,纵向关联用线性混合效应模型。

主要发现

  • 参与者61%为女性,年龄47.3±11.8岁,htTKV为834(IQR 495–1327)mL/m,eGFR为63.3±28.9 mL/min/1.73 m²,BHB中位浓度94(IQR 68–147)µmol/L。
  • 横断面分析中,BHB与eGFR及htTKV均无关联。
  • 纵向分析中,BHB与eGFR斜率正相关(B=0.35 mL/min/1.73 m²,95%CI 0.09–0.61,P=.007),但与肾脏增长无关。
  • 校正潜在混杂因素后,BHB浓度每翻倍与eGFR年变化率改善0.33 mL/min/1.73 m²相关(95%CI 0.09–0.57,P=.008)。

临床怎么用

  • 原文未给出临床实践推荐;结果仅来自观察性分析,支持提高BHB浓度可能减缓ADPKD肾功能下降的假设。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dysregulated energy metabolism is a recently discovered key feature of autosomal dominant polycystic kidney disease (ADPKD). Cystic cells depend on glucose and are poorly able to use other energy sources such as ketone bodies. Raising ketone body concentration reduced disease progression in animal models of polycystic kidney diseases. Therefore, we hypothesized that higher endogenous plasma beta-hydroxybutyrate (BHB) concentrations are associated with reduced disease progression in patients with ADPKD. METHODS: We analyzed data from 670 patients with ADPKD participating in the Developing Intervention Strategies to Halt Progression of ADPKD (DIPAK) cohort, a multi-center prospective observational cohort study. BHB was measured at baseline using nuclear magnetic resonance spectroscopy. Participants were excluded if they had type 2 diabetes, were using disease-modifying drugs (e.g. tolvaptan, somatostatin analogs), were not fasting or had missing BHB levels, leaving 521 participants for the analyses. Linear regression analyses were used to study cross-sectional associations and linear mixed-effect modeling for longitudinal associations. RESULTS: Of the participants, 61% were female, with an age of 47.3 ± 11.8 years, a height-adjusted total kidney volume (htTKV) of 834 [interquartile range (IQR) 495-1327] mL/m and an estimated glomerular filtration rate (eGFR) of 63.3 ± 28.9 mL/min/1.73 m2. The median concentration of BHB was 94 (IQR 68-147) µmol/L. Cross-sectionally, BHB was associated neither with eGFR nor with htTKV. Longitudinally, BHB was positively associated with eGFR slope {B = 0.35 mL/min/1.73 m2 [95% confidence interval (CI) 0.09 to 0.61], P = .007}, but not with kidney growth. After adjustment for potential confounders, every doubling in BHB concentration was associated with an improvement in the annual rate of eGFR by 0.33 mL/min/1.73 m2 (95% CI 0.09 to 0.57, P = .008). CONCLUSION: These observational analyses support the hypothesis that interventions that raise BHB concentration could reduce the rate of kidney function decline in patients with ADPKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Knol MGE, Bais T, Geertsema P, et al. Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD. Nephrol Dial Transplant. 2024. PMID: 37974030. doi:10.1093/ndt/gfad239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。